Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 13/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19065558 | 0.85 | DGAT1 (0.46) | DGAT1PDE10A | |
| SCHEMBL22000136 | 0.85 | DYRK1A (0.35) | DGAT1DYRK1A | |
| SCHEMBL19065500 | 0.80 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL31181701 | 0.80 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL27338948 | 0.80 | DGAT1 (0.54) | DGAT1PDE10A | |
| SCHEMBL19065595 | 0.79 | DGAT1 (0.37) | DGAT1PDE10A | |
| SCHEMBL21931533 | 0.77 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL19404674 | 0.75 | DGAT1 (0.47) | DGAT1PDE10A | |
| SCHEMBL19065358 | 0.74 | PIK3CD (0.42) | DGAT1 | |
| SCHEMBL31181688 | 0.74 | PIK3CD (0.42) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3792256-B1 | PYRIDINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2024-10-23 | — | — | EP | disclosed |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-04-09 | — | — | US | disclosed |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2024-01-02 | — | — | US | disclosed |
| US-20220340544-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2022-10-27 | — | — | US | disclosed |
| US-11396502-B2 | Substituted heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2022-07-26 | — | — | US | disclosed |
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2022-07-21 | — | — | US | disclosed |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| EP-3792256-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3400221-B1 | PYRAZOL / IMIDAZOL SUBSTITUTED PYRIDINES AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2020-08-26 | — | — | EP | disclosed |
| WO-2020102216-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| WO-2020102216-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200148667-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
| EP-3400221-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | Incyte Corporation (US) | 2018-11-14 | — | — | EP | disclosed |
| WO-2017120194-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION (US) | 2017-07-13 | — | — | WO | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | DGAT1 3641/4885DYRK1A 2066/4885PDE10A 817/4885 |
| US-11858930-B2 | Fused bicyclic RAF inhibitors and methods for use thereof | BRAF, RAF1, NRAS | DGAT1 3289/4885DYRK1A 295/4885PDE10A 2377/4885 |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | DGAT1 3641/4885DYRK1A 2066/4885PDE10A 817/4885 |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | DGAT1 3641/4885DYRK1A 2066/4885PDE10A 817/4885 |
| US-11396502-B2 | Substituted heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3CA, PIK3CG | DGAT1 2080/4885DYRK1A 4277/4885PDE10A 619/4885 |
| US-20220340544-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3CA, PIK3CG | DGAT1 2080/4885DYRK1A 4277/4885PDE10A 619/4885 |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | DGAT1 3641/4885DYRK1A 2066/4885PDE10A 817/4885 |
| US-20200148667-A1 | SUBSTITUTED HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3CA, PIK3CG | DGAT1 2080/4885DYRK1A 4277/4885PDE10A 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.